Evidence map›Paper›PMID 34046350›Full record

ArticleFrontiers in oncology2021

A Novel Ferroptosis Related Gene Signature for Prognosis Prediction in Patients With Colon Cancer.

Jianhua Nie, Dan Shan, Shun Li, Shuyuan Zhang, Xiaolin Zi, Fan Xing, Jiaqi Shi, Caiqi Liu, Tianjiao Wang, Xiaoyuan Sun and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 51 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. 3International journal of molecular sciences · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Jianhua NieDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Dan ShanDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Shun LiDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Shuyuan ZhangDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Xiaolin ZiDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Fan XingDepartment of Radiation Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Jiaqi ShiDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Caiqi LiuDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Tianjiao WangThe Seventh Department of the Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, China.
Xiaoyuan SunDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Qian ZhangDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Meng ZhouDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Shengnan LuoDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Hongxue MengDepartment of Pathology, Harbin Medical University Cancer Hospital, Harbin, China.
Yanqiao ZhangDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Tongsen ZhengDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Third Affiliated Hospital of Harbin Medical University · CNHarbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeColon cancer (CC) is a serious disease burden. The prognosis of patients with CC is different, so looking for effective biomarkers to predict prognosis is vitally important. Ferroptosis is a promising therapeutic and diagnosis strategy in CC. However, the role of ferroptosis in prognosis of CC has not been studied. The aim of the study is to build a prognosis model related ferroptosis, and provide clues for further therapy of CC.

methodsThe RNA-seq data were from TCGA (training group) and GEO (testing group). The R language and Perl language were used to process and analyze data. LASSO regression analysis was used to build the prognosis model. ssGSEA was used to compare the immune status between two groups. Immunohistochemistry was used to detect expression of AKR1C1 and CARS1 in colon cancer tissues and adjacent tissues.

resultsThe prognosis model consisted of five ferroptosis related genes (AKR1C1, ALOX12, FDFT1, ATP5MC3, and CARS1). The area under curve (AUC) at 1-, 2-, and 3-year were 0.668, 0.678, and 0.686, respectively. The high- and low-risk patients had significant survival probability and could be clearly distinguished by the PCA and t-SNE analysis. The multivariate cox regression analysis also showed the riskscore is an independent prognosis factor. Importantly, we found that the immune status between high- and low-risk patients were different obviously, such as CD8

conclusionOur ferroptosis prognosis signature could predict survival of CC patients to a certain degree. And the crosstalk between ferroptosis and immune, especially STING need further studies.

Indexed as

colon cancerferroptosisimmune statusprognosisSTING

Identifiers

PMID34046350
PMCPMC8144717
OpenAlexW3160538422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.